Molecular Profile Detail

Profile Name MET del exon14
Gene Variant Detail

MET del exon14 (gain of function)

Relevant Treatment Approaches MET Antibody MET Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET del exon14 stomach carcinoma sensitive MET Antibody SAIT301 Preclinical - Patient cell culture Actionable In a preclinical study, SAIT301 inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 lung cancer decreased response MET Antibody MET Inhibitor Emibetuzumab Preclinical - Pdx Actionable In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 Advanced Solid Tumor sensitive MET Inhibitor Capmatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing a deletion of MET exon 14 were sensitive to Capmatinib (INC280) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 lung adenocarcinoma predicted - sensitive MET Inhibitor Crizotinib Case Reports/Case Series Actionable In a clinical study, three patients with lung adenocarcinoma harboring a MET exon 14 skipping mutation demonstrated partial responses when treated with Xalkori (crizotinib) (PMID: 25971939). 25971939
MET del exon14 lung squamous cell carcinoma predicted - sensitive MET Inhibitor Capmatinib Case Reports/Case Series Actionable In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring a MET exon 14 skipping mutation (PMID: 25971938). 25971938
MET del exon14 stomach cancer sensitive MET Antibody SYM015 Preclinical - Cell line xenograft Actionable In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 lung non-small cell carcinoma sensitive MET Antibody MET Inhibitor KTN0073-IgG1 Preclinical - Cell culture Actionable In a preclinical study, KTN0073-IgG1 inhibited growth of a non-small cell lung cancer cell line harboring deletion of MET exon 14 in culture (PMID: 27550450). 27550450
MET del exon14 stomach cancer decreased response MET Antibody MET Inhibitor Emibetuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 stomach carcinoma sensitive MET Inhibitor Cabozantinib Preclinical - Cell culture Actionable In a preclinical study, Cometriq (cabozantinib) inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 colorectal cancer sensitive MET Inhibitor Cabozantinib Preclinical - Patient cell culture Actionable In a preclinical study, Cometriq (cabozantinib) inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 lung non-small cell carcinoma predicted - sensitive MET Inhibitor Savolitinib Phase II Actionable In a Phase II trial, Savolitinib (AZD6094) treatmetn resulted in partial response in 51.6% (16/31) and stable disease in 32.3% (10/31) of patients with pulmonary sarcomatoid carcinoma (n=14) or other types of non-small cell lung cancer (n=20) harboring MET exon 14 skipping mutations (AACR Annual Meeting 2019, Abstract CT301; NCT02897479). detail...
MET del exon14 colorectal cancer sensitive MET Inhibitor PHA-665752 Preclinical - Patient cell culture Actionable In a preclinical study, PHA-665752 inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 colorectal cancer sensitive MET Inhibitor Crizotinib Preclinical - Patient cell culture Actionable In a preclinical study, Xalkori (crizotinib) inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 colorectal cancer sensitive MET Antibody SAIT301 Preclinical - Patient cell culture Actionable In a preclinical study, SAIT301 inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 Advanced Solid Tumor sensitive MET Inhibitor Crizotinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing a deletion of MET exon 14 were sensitive to Xalkori (crizotinib) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 Advanced Solid Tumor sensitive MET Antibody SYM015 Preclinical - Pdx & cell culture Actionable In a preclinical study, Sym015 inhibited growth of cancer cell lines harboring a deletion of MET exon 14 in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models with deletion of MET exon 14 (Cancer Res July 15 2016 (76) (14 Supplement) 1219). detail...
MET del exon14 lung cancer sensitive MET Inhibitor Glesatinib Preclinical - Cell culture Actionable In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in lung cancer cells harboring a deletion of MET exon 14 and loss of the wild-type MET allele in culture (PMID: 28765324). 28765324
MET del exon14 stomach carcinoma sensitive MET Inhibitor PHA-665752 Preclinical - Patient cell culture Actionable In a preclinical study, PHA-665752 inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 stomach cancer sensitive MET Inhibitor Glesatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in gastric cancer cells harboring a deletion of MET exon 14 and amplification of the mutant allele in culture, and resulted in tumor regression in cell line xenograft models (PMID: 28765324). 28765324
MET del exon14 lung adenocarcinoma predicted - sensitive MET Inhibitor Glesatinib Case Reports/Case Series Actionable In a clinical case study, a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation demonstrated a 66% reduction in target lesion size and maintained a partial response for 7 months when treated with Glesatinib (MGCD265) (PMID: 28765324). 28765324
MET del exon14 lung non-small cell carcinoma sensitive MET Antibody Onartuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, Onartuzumab inhibited tumor growth and decreased MET expression in a non-small cell lung cancer xenograft model harboring a deletion of MET exon 14 (PMID: 23882082). 23882082
MET del exon14 lung cancer sensitive MET Antibody SYM015 Preclinical - Pdx Actionable In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 Advanced Solid Tumor sensitive MET Inhibitor Glesatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing deletion of MET exon 14 were sensitive to Glesatinib (MGCD265) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 stomach carcinoma sensitive MET Inhibitor Crizotinib Preclinical - Patient cell culture Actionable In a preclinical study, Xalkori (crizotinib) inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
Clinical Trial Phase Therapies Title Recruitment Status
NCT02648724 Phase Ib/II SYM015 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Recruiting
NCT03260491 Phase I U3-1402 U3-1402 in Metastatic or Unresectable EGFR-mutant Non-Small Cell Lung Cancer Recruiting
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT02465060 Phase II Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT02750215 Phase II Capmatinib A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Recruiting